Statement: FDA Must Reject Tanezumab as a Treatment for Osteoarthritis Due to Unacceptable Dangers, Little to No Benefit
Polling Memo: Public Anger About Corporate Power Dominant Factor in Views on Trade and TPP. July 13, 2016